Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine
Objective: We constructed two DNA vaccines containing the receptor-binding domain (RBD) genes of multiple SARS-CoV-2 variants and used them in combination with inactivated vaccines in a variety of different protocols to explore potential novel immunization strategies against SARS-CoV-2 variants. Met...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/6/929 |
| _version_ | 1797481587071254528 |
|---|---|
| author | Ziyan Meng Danjing Ma Suqin Duan Jingjing Zhang Rong Yue Xinghang Li Yang Gao Xueqi Li Fengyuan Zeng Xiangxiong Xu Guorun Jiang Yun Liao Shengtao Fan Zhenye Niu Dandan Li Li Yu Heng Zhao Xingli Xu Lichun Wang Ying Zhang Longding Liu Qihan Li |
| author_facet | Ziyan Meng Danjing Ma Suqin Duan Jingjing Zhang Rong Yue Xinghang Li Yang Gao Xueqi Li Fengyuan Zeng Xiangxiong Xu Guorun Jiang Yun Liao Shengtao Fan Zhenye Niu Dandan Li Li Yu Heng Zhao Xingli Xu Lichun Wang Ying Zhang Longding Liu Qihan Li |
| author_sort | Ziyan Meng |
| collection | DOAJ |
| description | Objective: We constructed two DNA vaccines containing the receptor-binding domain (RBD) genes of multiple SARS-CoV-2 variants and used them in combination with inactivated vaccines in a variety of different protocols to explore potential novel immunization strategies against SARS-CoV-2 variants. Methods: Two DNA vaccine candidates with different signal peptides (namely, secreted and membrane signal peptides) and RBD protein genes of different SARS-CoV-2 strains (Wuhan-Hu-1, B.1.351, B.1.617.2, C.37) were used. Four different combinations of DNA and inactivated vaccines were tested, namely, Group A: three doses of DNA vaccine; B: three doses of DNA vaccine and one dose of inactivated vaccine; C: two doses of inactivated vaccine and one dose of DNA vaccine; and D: coadministration of DNA and inactivated vaccines in two doses. Subgroups were grouped according to the signal peptide used (subgroup 1 contained secreted signal peptides, and subgroup 2 contained membrane signal peptides). The in vitro expression of the DNA vaccines, the humoral and cellular immunity responses of the immunized mice, the immune cell population changes in local lymph nodes, and proinflammatory cytokine levels in serum samples were evaluated. Results: The antibody responses and cellular immunity in Group A were weak for all SARS-CoV-2 strains; for Group B, there was a great enhancement of neutralizing antibody (Nab) titers against the B.1.617.2 variant strain. Group C showed a significant increase in antibody responses (NAb titers against the Wuhan-Hu-1 strain were 768 and 1154 for Group C1 and Group C2, respectively, versus 576) and cellular immune responses, especially for variant B.1.617.2 (3240 (<i>p</i> < 0.001) and 2430 (<i>p</i> < 0.05) for Group C1 and Group C2, versus 450); Group D showed an improvement in immunogenicity. Group C induced higher levels of multiple cytokines. Conclusion: The DNA vaccine candidates we constructed, administered as boosters, could enhance the humoral and cellular immune responses of inactivated vaccines against COVID-19, especially for B.1.617.2. |
| first_indexed | 2024-03-09T22:17:43Z |
| format | Article |
| id | doaj.art-e74a186f9f1a4392ac103879e1c173cc |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:17:43Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-e74a186f9f1a4392ac103879e1c173cc2023-11-23T19:21:35ZengMDPI AGVaccines2076-393X2022-06-0110692910.3390/vaccines10060929Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated VaccineZiyan Meng0Danjing Ma1Suqin Duan2Jingjing Zhang3Rong Yue4Xinghang Li5Yang Gao6Xueqi Li7Fengyuan Zeng8Xiangxiong Xu9Guorun Jiang10Yun Liao11Shengtao Fan12Zhenye Niu13Dandan Li14Li Yu15Heng Zhao16Xingli Xu17Lichun Wang18Ying Zhang19Longding Liu20Qihan Li21Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaYunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, ChinaObjective: We constructed two DNA vaccines containing the receptor-binding domain (RBD) genes of multiple SARS-CoV-2 variants and used them in combination with inactivated vaccines in a variety of different protocols to explore potential novel immunization strategies against SARS-CoV-2 variants. Methods: Two DNA vaccine candidates with different signal peptides (namely, secreted and membrane signal peptides) and RBD protein genes of different SARS-CoV-2 strains (Wuhan-Hu-1, B.1.351, B.1.617.2, C.37) were used. Four different combinations of DNA and inactivated vaccines were tested, namely, Group A: three doses of DNA vaccine; B: three doses of DNA vaccine and one dose of inactivated vaccine; C: two doses of inactivated vaccine and one dose of DNA vaccine; and D: coadministration of DNA and inactivated vaccines in two doses. Subgroups were grouped according to the signal peptide used (subgroup 1 contained secreted signal peptides, and subgroup 2 contained membrane signal peptides). The in vitro expression of the DNA vaccines, the humoral and cellular immunity responses of the immunized mice, the immune cell population changes in local lymph nodes, and proinflammatory cytokine levels in serum samples were evaluated. Results: The antibody responses and cellular immunity in Group A were weak for all SARS-CoV-2 strains; for Group B, there was a great enhancement of neutralizing antibody (Nab) titers against the B.1.617.2 variant strain. Group C showed a significant increase in antibody responses (NAb titers against the Wuhan-Hu-1 strain were 768 and 1154 for Group C1 and Group C2, respectively, versus 576) and cellular immune responses, especially for variant B.1.617.2 (3240 (<i>p</i> < 0.001) and 2430 (<i>p</i> < 0.05) for Group C1 and Group C2, versus 450); Group D showed an improvement in immunogenicity. Group C induced higher levels of multiple cytokines. Conclusion: The DNA vaccine candidates we constructed, administered as boosters, could enhance the humoral and cellular immune responses of inactivated vaccines against COVID-19, especially for B.1.617.2.https://www.mdpi.com/2076-393X/10/6/929SARS-CoV-2COVID-19DNA vaccineinactivated vaccinevariantsRBD |
| spellingShingle | Ziyan Meng Danjing Ma Suqin Duan Jingjing Zhang Rong Yue Xinghang Li Yang Gao Xueqi Li Fengyuan Zeng Xiangxiong Xu Guorun Jiang Yun Liao Shengtao Fan Zhenye Niu Dandan Li Li Yu Heng Zhao Xingli Xu Lichun Wang Ying Zhang Longding Liu Qihan Li Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine Vaccines SARS-CoV-2 COVID-19 DNA vaccine inactivated vaccine variants RBD |
| title | Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine |
| title_full | Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine |
| title_fullStr | Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine |
| title_full_unstemmed | Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine |
| title_short | Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine |
| title_sort | immunological study of combined administration of sars cov 2 dna vaccine and inactivated vaccine |
| topic | SARS-CoV-2 COVID-19 DNA vaccine inactivated vaccine variants RBD |
| url | https://www.mdpi.com/2076-393X/10/6/929 |
| work_keys_str_mv | AT ziyanmeng immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT danjingma immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT suqinduan immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT jingjingzhang immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT rongyue immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT xinghangli immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT yanggao immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT xueqili immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT fengyuanzeng immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT xiangxiongxu immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT guorunjiang immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT yunliao immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT shengtaofan immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT zhenyeniu immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT dandanli immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT liyu immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT hengzhao immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT xinglixu immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT lichunwang immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT yingzhang immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT longdingliu immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine AT qihanli immunologicalstudyofcombinedadministrationofsarscov2dnavaccineandinactivatedvaccine |